Search for a command to run...
Chronic pancreatitis remains an urgent medical and social problem due to the complexity of diagnosis and the high incidence of complications. One of the most important clinical manifestations of сhronic pancreatitis is exocrine pancreatic insufficiency (EPI), which is accompanied by maldigestion, nutritional deficiencies and an increased risk of infectious and systemic complications. Pancreatic enzyme replacement therapy is the basic method of treating this condition. Recently, there has been growing interest in enzyme preparations of non‑animal origin due to a number of advantages — broad substrate specificity, stability of activity, and the absence of the need for activation by bile acids, which makes them promising in clinical practice, especially in patients with biliary pancreatitis. Objective — to investigate and compare the effectiveness of enzyme preparations of animal and non‑animal origin in patients with biliary pancreatitis. Materials and methods. The study included 78 patients with biliary pancreatitis and EPI. The inclusion criteria were a confirmed diagnosis of biliary pancreatitis and EPI, and the exclusion criteria were concomitant severe liver, gastrointestinal diseases and oncologic pathology. The diagnosis was based on clinical data, laboratory parameters (amylase, lipase, glycemia, fecal elastase, etc.), instrumental methods (ultrasound, upper endoscopy) and PAGI‑SYM (Patient Assessment of Gastrointestinal Disorders‑Symptom Severity Index) and PEI‑Q questionnaires (Qualitative Assessment of the Symptoms and Impact of Pancreatic Exocrine Insufficiency). Patients were divided into two groups: the main group (n=40) received basic therapy and the enzyme preparation of non‑animal origin (Pangest®, Farmak, Ukraine) , the control group (n=38) received basic therapy and enzyme preparation of animal origin (pancreatin). The duration of the study was 4 weeks. Results. Both treatment regimens (Pangest® and pancreatin) provided improvement in clinical symptoms, laboratory and coproscopic parameters in patients with biliary pancreatitis and EPI. However, the effectiveness of Pangest® as a significant decrease in integral scores, a faster reduction in dyspeptic manifestations and an improvement in life quality. Laboratory parameters (amylase, lipase, glycemia) normalized faster in the main group, and coproscopy confirmed the restoration of digestive processes in a larger proportion of patients (90% versus 78.9%). Conclusions. Enzyme replacement therapy is an effective component of the treatment of biliary pancreatitis with EPI. The use of the preparation Pangest® demonstrated better clinical efficacy and more pronounced improvement of digestive function compared to standard pancreatin, which indicates its advantages for the complex therapy of patients with biliary pancreatitis.